-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and ...
Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data. RLYB212, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback